These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 31490767)

  • 81. FLT3-ITD confers resistance to the PI3K/Akt pathway inhibitors by protecting the mTOR/4EBP1/Mcl-1 pathway through STAT5 activation in acute myeloid leukemia.
    Nogami A; Oshikawa G; Okada K; Fukutake S; Umezawa Y; Nagao T; Kurosu T; Miura O
    Oncotarget; 2015 Apr; 6(11):9189-205. PubMed ID: 25826077
    [TBL] [Abstract][Full Text] [Related]  

  • 82. Inhibitors Targeting STAT5 Signaling in Myeloid Leukemias: New Tetrahydroquinoline Derivatives with Improved Antileukemic Potential.
    Polomski M; Brachet-Botineau M; Juen L; Viaud-Massuard MC; Gouilleux F; Prié G
    ChemMedChem; 2021 Mar; 16(6):1034-1046. PubMed ID: 33275308
    [TBL] [Abstract][Full Text] [Related]  

  • 83. Effects of Pimozide Derivatives on pSTAT5 in K562 Cells.
    Rondanin R; Simoni D; Maccesi M; Romagnoli R; Grimaudo S; Pipitone RM; Meli M; Cascio A; Tolomeo M
    ChemMedChem; 2017 Aug; 12(15):1183-1190. PubMed ID: 28657677
    [TBL] [Abstract][Full Text] [Related]  

  • 84. Targeting STAT5 in hematologic malignancies through inhibition of the bromodomain and extra-terminal (BET) bromodomain protein BRD2.
    Liu S; Walker SR; Nelson EA; Cerulli R; Xiang M; Toniolo PA; Qi J; Stone RM; Wadleigh M; Bradner JE; Frank DA
    Mol Cancer Ther; 2014 May; 13(5):1194-205. PubMed ID: 24435449
    [TBL] [Abstract][Full Text] [Related]  

  • 85. STAT5 and STAT5 Inhibitors in Hematological Malignancies.
    Tolomeo M; Meli M; Grimaudo S
    Anticancer Agents Med Chem; 2019; 19(17):2036-2046. PubMed ID: 31490767
    [TBL] [Abstract][Full Text] [Related]  

  • 86. Signal transducer and activator of transcription (STAT)-5: an opportunity for drug development in oncohematology.
    Recio C; Guerra B; Guerra-Rodríguez M; Aranda-Tavío H; Martín-Rodríguez P; de Mirecki-Garrido M; Brito-Casillas Y; García-Castellano JM; Estévez-Braun A; Fernández-Pérez L
    Oncogene; 2019 Jun; 38(24):4657-4668. PubMed ID: 30783189
    [TBL] [Abstract][Full Text] [Related]  

  • 87. JAK/STAT signaling in hematological malignancies.
    Vainchenker W; Constantinescu SN
    Oncogene; 2013 May; 32(21):2601-13. PubMed ID: 22869151
    [TBL] [Abstract][Full Text] [Related]  

  • 88. STAT5 signaling in normal and pathologic hematopoiesis.
    Bunting KD
    Front Biosci; 2007 May; 12():2807-20. PubMed ID: 17485261
    [TBL] [Abstract][Full Text] [Related]  

  • 89. The JAK-STAT pathway: a therapeutic target in hematological malignancies.
    Ferrajoli A; Faderl S; Ravandi F; Estrov Z
    Curr Cancer Drug Targets; 2006 Dec; 6(8):671-9. PubMed ID: 17168672
    [TBL] [Abstract][Full Text] [Related]  

  • 90. Implications of STAT3 and STAT5 signaling on gene regulation and chromatin remodeling in hematopoietic cancer.
    Wingelhofer B; Neubauer HA; Valent P; Han X; Constantinescu SN; Gunning PT; Müller M; Moriggl R
    Leukemia; 2018 Aug; 32(8):1713-1726. PubMed ID: 29728695
    [TBL] [Abstract][Full Text] [Related]  

  • 91. The many faces of Janus kinase.
    Seavey MM; Dobrzanski P
    Biochem Pharmacol; 2012 May; 83(9):1136-45. PubMed ID: 22209716
    [TBL] [Abstract][Full Text] [Related]  

  • 92. Novel dual Src/Abl inhibitors for hematologic and solid malignancies.
    Schenone S; Brullo C; Musumeci F; Botta M
    Expert Opin Investig Drugs; 2010 Aug; 19(8):931-45. PubMed ID: 20557276
    [TBL] [Abstract][Full Text] [Related]  

  • 93.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 94.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 95.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 96.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 97.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 98.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 99.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 100.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.